Atom Investors’s Arcus Biosciences RCUS Stock Holding History

Atom Investors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-47,933	Closed	-$1.19M	–	607
2020 Q2	$1.19M	Buy	+47,933	New	+$1.29M	0.08%	195

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Atom Investors's RCUS Position: Q3 2020 in Review

Atom Investors sold out of Arcus Biosciences (RCUS) in Q3 2020, closing a stake of 47,933 shares — an estimated $1.19M sold.

Atom Investors first reported a position in RCUS in Q2 2020 and held it in 1 quarter. The position peaked at $1.19M in Q2 2020. 128 funds tracked by Wall St. Rank hold RCUS as of Q3 2020.

Atom Investors reported no remaining Arcus Biosciences position as of Q3 2020 after selling out during the quarter.
Atom Investors sold 47,933 Arcus Biosciences shares in Q3 2020, an estimated $1.19M.
Atom Investors first reported a position in Arcus Biosciences in Q2 2020 and held it in 1 quarter.
Atom Investors's Arcus Biosciences position peaked at $1.19M in Q2 2020.
128 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2020.

Based on Atom Investors's 13F filing for Q3 2020, filed 13 Nov 2020.